Death at final · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment showed no clear difference in death at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
End‐stage renal disease · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment probably leads to lower end‐stage kidney disease at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
Total remission (complete or partial) at final · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment probably leads to higher total remission (complete or partial) at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
Complete remission · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment probably leads to higher complete remission at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
Relapse · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment may leads to higher recurrence of disease (relapse) at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (low certainty).
1 finding from 1 review
100% increase in SCr at final · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment probably leads to lower 100% increase in serum creatinine at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
Adverse events ‐ temporary or permanent discontinuation/hospitalisation at final · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment probably leads to higher adverse events: temporary/permanent discontinuation or… compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
Adverse events: infection at 3 years · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether immunosuppressive treatment changes adverse events: infection at 3 years compared with placebo/no treatment/non‐immunosuppressive supportive treatment (very low certainty).
1 finding from 1 review
Adverse events: malignancy · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether immunosuppressive treatment changes adverse events: malignancy at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (very low certainty).
1 finding from 1 review
Relapse during treatment (4 to 12 months) · SSNS in children
Levamisole may leads to lower relapse during treatment (4 to 12 months) compared with steroids or placebo or both, or no treatment (low certainty).
1 finding from 1 review
Death (any cause) · people IgA nephropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission of proteinuria · people IgA nephropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission of haematuria · people IgA nephropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse of proteinuria · people IgA nephropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
> 50% increase in SCr · people IgA nephropathy
Renin‐angiotensin system inhibition may leads to lower > 50% increase in SCr compared with other supportive care treatment (low certainty).
1 finding from 1 review
Proteinuria · people IgA nephropathy
1 finding from 1 review
Kidney failure or doubling of SCr · people IgA nephropathy
Renin‐angiotensin system inhibition showed no clear difference in kidney failure or doubling of SCr compared with placebo or no treatment (low certainty).
1 finding from 1 review
Complete remission of proteinuria · people IgA nephropathy
Renin‐angiotensin system inhibition showed no clear difference in remission of proteinuria: complete remission compared with placebo or no treatment (low certainty).
1 finding from 1 review
Remission of haematuria · people IgA nephropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse of proteinuria · people IgA nephropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found